《異動股》中旭未來(09890.HK)續瀉近18%創逾一個月低
中旭未來(09890.HK)承過去三連跌勢,今日(20日)低開4.8%後跌幅急擴,最低見18.88元創逾一個月低。現報19元,瀉17.8%,成交125.5萬股,涉資2,548.62萬元。
該股是內地網絡遊戲產品發行商,去年9月底以每股14元上市,自去年11月中旬起展開升浪,至今年1月底曾升見72.45元歷史高,隨後於2月2日單日暴挫約76%後逐漸回升,至3月1日再單日急挫45.4%收報29.5元,隨後輾轉走低。
恆指公司上月公佈季檢結果,將公司納入恆生綜合指數小型股,並且將成爲港股通標的,將於3月4日生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.